Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the third quarter of 2013 highlighted by the strong performance of key marketed products such as Yervoy, Orencia and Sprycel, the presentation of important clinical data for its immuno-oncology pipeline, and the presentation of key cardiovascular outcomes data for Onglyza®. The company also confirmed GAAP EPS and non-GAAP EPS guidance ranges for 2013.
Help employers find you! Check out all the jobs and post your resume.
